Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.77 |
| ▸ | CES2 | O00748 | 5/20 | 0.71 |
| ▸ | CES1 | P23141 | 5/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16915217 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL6899719 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL28767487 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL8458168 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL29287856 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL3950801 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL6344027 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL5126810 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL609881 | 1.00 | FAAH (0.77) | FAAHCES2CES1GPR84PPARG | |
| SCHEMBL1367098 | 0.97 | FAAH (0.73) | FAAHCES2CES1GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638964-A1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113331-A1 | NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-29 | — | — | WO | claimed |
| US-20040102350-A1 | Compositions for treating shoes and methods and articles employing same | BAKER KEITH HOMER (US) | 2004-05-27 | — | — | US | claimed |
| US-20040067322-A1 | Compositions for treating shoes and methods and articles employing same | BAKER KEITH HOMER (US) | 2004-04-08 | — | — | US | claimed |
| US-20030114331-A1 | Compositions for treating shoes and methods and articles employing same | THE PROCTER & GAMBLE COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20020119907-A1 | Compositions for treating shoes and methods and articles employing same | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | claimed |
| EP-1222244-A1 | COMPOSITIONS FOR TREATING SHOES AND METHODS AND ARTICLES EMPLOYING SAME | The Procter & Gamble Company (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2001030955-A9 | COMPOSITIONS FOR TREATING SHOES AND METHODS AND ARTICLES EMPLOYING SAME | PROCTER & GAMBLE (US) | 2002-07-04 | — | — | WO | claimed |
| US-20020082188-A1 | Compositions for treating shoes and methods and articles employing same | THE PROCTER & GAMBLE COMPANY | 2002-06-27 | — | — | US | claimed |
| WO-2001030955-A1 | COMPOSITIONS FOR TREATING SHOES AND METHODS AND ARTICLES EMPLOYING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-03 | — | — | WO | claimed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| EP-2683371-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | Cereno Scientific AB (SE) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012120262-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | LARSSON PIA (SE) | 2012-09-13 | — | — | WO | disclosed |
| CN-101296897-A | PPAR-modulating biaromatic compounds | GALDERMA RES & DEV (FR) | 2008-10-29 | — | — | CN | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| US-6861396-B2 | Compositions for pre-treating shoes and methods and articles employing same | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1360256-A2 | COMPOSITIONS FOR PRE-TREATING SHOES AND METHODS AND ARTICLES EMPLOYING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002066568-A2 | COMPOSITIONS FOR PRE-TREATING SHOES AND METHODS AND ARTICLES EMPLOYING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020077263-A1 | Compositions for pre-treating shoes and methods and articles employing same | PROCTER & GAMBLE COMPANY, THE | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | FAAH 204/4885CES2 1486/4885CES1 540/4885 |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC4 | FAAH 177/4885CES2 902/4885CES1 523/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | FAAH 235/4885CES2 1412/4885CES1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.